Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon Salazar

Showing results (71-80 of 115) with videos related to

Pageof 12
Sort By:
The Oncologist|December 16, 2017
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine TumorsRamon Salazar, Rocio Garcia-Carbonero, Steven K Libutti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2010
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancerRamon Salazar, Paul Roepman, Gabriel Capella, et al.
Neuroendocrinology|August 31, 2013
Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE)Elena Martin-Perez, Jaume Capdevila, Daniel Castellano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2013
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trialJosep Tabernero, Rocio Garcia-Carbonero, James Cassidy, et al.
Cell|November 27, 2012
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signalingSidong Huang, Michael Hölzel, Theo Knijnenburg, et al.
JAMA Oncology|November 24, 2017
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational StatusJulien Taieb, Hampig Raphael Kourie, Jean-François Emile, et al.
International Journal of Cancer|February 11, 2026
Post-surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detectionAndrei Kudriavtsev, Saidi Daoud, Catalina Isabel Cofre Muñoz, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 3, 2025
Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospectsPilar Mur, Anna Pozuelo, Josep Tabernero, et al.
Molecular Cancer Therapeutics|June 20, 2017
Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Daniel Azuara, Rocio Garcia-Carbonero, et al.
The Lancet. Oncology|November 22, 2012
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trialAimery de Gramont, Eric Van Cutsem, Hans-Joachim Schmoll, et al.
Pageof 12

Showing results (71-80 of 115) with videos related to

Sort By:
Pageof 12
The Oncologist|December 16, 2017
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine TumorsRamon Salazar, Rocio Garcia-Carbonero, Steven K Libutti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2010
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancerRamon Salazar, Paul Roepman, Gabriel Capella, et al.
Neuroendocrinology|August 31, 2013
Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE)Elena Martin-Perez, Jaume Capdevila, Daniel Castellano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2013
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trialJosep Tabernero, Rocio Garcia-Carbonero, James Cassidy, et al.
Cell|November 27, 2012
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signalingSidong Huang, Michael Hölzel, Theo Knijnenburg, et al.
JAMA Oncology|November 24, 2017
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational StatusJulien Taieb, Hampig Raphael Kourie, Jean-François Emile, et al.
International Journal of Cancer|February 11, 2026
Post-surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detectionAndrei Kudriavtsev, Saidi Daoud, Catalina Isabel Cofre Muñoz, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 3, 2025
Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospectsPilar Mur, Anna Pozuelo, Josep Tabernero, et al.
Molecular Cancer Therapeutics|June 20, 2017
Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Daniel Azuara, Rocio Garcia-Carbonero, et al.
The Lancet. Oncology|November 22, 2012
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trialAimery de Gramont, Eric Van Cutsem, Hans-Joachim Schmoll, et al.
Pageof 12